Amgen Urges Balance In US Biosimilars Policy
Company Outlines Key Elements For A Successful Marketplace For Biosimilars
Amgen’s recent study on biosimilars trends has outlined the importance of US policy in the success of the biosimilars marketplace, insisting on the importance of increased competition and effective reimbursement and education policies. But with interests in innovative biologics as well as biosimilars, the company has also emphasized that pro-biosimilars policies must not stifle innovation and compromise free competition.
You may also be interested in...
Senators press for sharing of FDA applications with PTO as Woodcock letter seeks collaboration on everything from PTAB to patent term extensions to ‘possible misuse of the patent system.’
A group of organizations representing patients, consumers, providers and taxpayers have extended support to the zero co-pay policy which would decrease significant barriers for prescribing lower-cost biosimilars. The stakeholders have urged the US HHS and CMS to reform Medicare payment policies, “which would allow patients better access to lower cost biosimilars.”
Draft US legislation that would seek to encourage biosimilar adoption by temporarily boosting reimbursement has received the backing of the AAM.